New Hypertension Drug and Topical Gene Therapy Gain Approvals in the US and UK
Two new treatments across very different therapeutic areas and modalities have received regulatory approvals in the U.S. and UK.
AstraZeneca’s Baxfendy (baxdrostat) has been approved by the U.S. FDA as a new treatment option for adults with uncontrolled hypertension, in combination with other antihypertensive medicines.
Meanwhile, Krystal Biotech’s VYJUVEK (beremagene geperpavec-svdt) has been approved by the UK MHRA for dystrophic epidermolysis bullosa (DEB) from birth in patients with COL7A1 mutations.
Baxfendy (baxdrostat) | AstraZeneca
- For adults with uncontrolled hypertension
- Used with other antihypertensive medicines
- Approved as an aldosterone synthase inhibitor
- A new option in cardiovascular, renal and metabolic care
Baxfendy targets aldosterone production, offering a new mechanism-based approach in hypertension care.
VYJUVEK (beremagene geperpavec-svdt) | Krystal Biotech
- For dystrophic epidermolysis bullosa with COL7A1 mutations
- Approved from birth
- Topical gene therapy applied directly to skin wounds
- Uses an HSV-1 vector to deliver COL7A1
VYJUVEK shows how gene therapy can move beyond invasive or specialised-centre settings toward more practical clinical use.
Together, these approvals show how therapeutic innovation is diversifying, from new mechanisms in chronic disease to topical gene therapy designed for real-world implementation.
As a talent partner focused on CGT, regenerative medicine and advanced therapies, Greenstaff Life Sciences supports the specialist capabilities and talent strategies required to implement new therapeutic modalities.
We extend our congratulations to the teams at AstraZeneca and Krystal Biotech.